295 results about "Vector system" patented technology

Systems, devices and automated processes are described for automated enhancement of metadata in a database of information about movies, television shows or other media programs. Gaps or errors in metadata describing the different programs in the database can be corrected using a digital architecture in which one or more sources are queried for missing information. Queries may be directed toward a large language model (LLM) or other artificial intelligence (AI) engine, if desired, that represents information about the media programs as embedded vectors that can be compared to query data to identify additional information about the media programs.

Systems and methods for forecasting data drift for model monitoring. In some aspects, the system receives a current explainability vector for a machine learning model and a data drift vector for historical data profiles. The machine learning model is trained on historical data including values for a first set of features. The system generates a projected synthetic dataset using the data drift vector and updates the machine learning model based on the projected synthetic dataset. Using the current explainability vector and a future explainability vector for the updated model, the system generates a second set of features and determines a drift threshold vector for the second set of features based on values in the explainability vectors. The system determines a discrepancy score for each feature of the second set of features. The system generates an alert including features in the second set of features and their associated discrepancy scores.

The present letter invention provides an engineered AAV capsid in which at least one protein on the capsid is modified to include an n-mer motif that promotes transduction of the capsid into the central nervous system (CNS) by interaction with a transferrin receptor. Further embodiments provide a carrier system comprising one or more carriers encoding an AAV capsid and a method of delivering a cargo to a CNS. The methods comprise administering an AAV capsid according to embodiments described herein in vivo or in vitro, and the AVV capsid comprises one or more carrier molecules.

Apparatuses, systems, and methods for machine learning (ML) modeling of a system operating on multi-vector objects are generally discussed herein. A method includes receiving, by an ML model, a multi-vector object as an input, the multi-vector object representing a state of a multi-vector system. The method includes operating, by an ML model, a multi-vector input using a Crifford layer to generate a multi-vector output representing a state of a multi-vector system responsive to the multi-vector input, the Crifford layer including neurons implementing a multi-vector kernel.

Described herein are targeting moieties that can be capable of specifically targeting muscle cells and can include an n-mer motif. In some embodiments, the n-mer motif contains an RGD motif. Also described herein are vector systems, particles, polypeptides that can encode and / or contain one or more targeting moieties. Also described herein are methods of delivering a cargo to a cell, such as a muscle cell, using one or more of the targeting moieties described herein.

The present invention relates to the field of in vitro transcription, and particularly to a plasmid backbone capable of improving the stability of polyadenylate tails. The present invention provides an expression cassette, which sequentially includes: the rop gene, the replicon ori, and the resistance gene; the rop gene, the replicon ori, and the resistance gene are connected by a linking fragment. The present invention has established a low-copy pmRVacSL and a medium-copy pmRVacM plasmid vector system through artificial modification. Since pmRVacSL is a low-copy vector, the yield of plasmid DNA is relatively low. The pmRVacM plasmid backbone solves the problem of relatively low plasmid DNA yield of pmRVacSL. This vector system can not only maintain the stable replication of polyA tail sequences of more than 150 bp, but also quickly add genes of interest and polyadenylate (polyA) sequences, and efficiently and rapidly obtain the DNA template for in vitro transcription of the target mRNA.

The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with mutations in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein. These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.

The present invention relates to a composition and a method for expressing an OTOF gene by a dual-vector system. Specifically provided are a fusion polypeptide, comprising an otoferlin protein portion, and an intein system portion. The gene encoding OTOF is transferred into the cell by means of a recombinant AAV dual-vector system.

The invention discloses a method for rapidly establishing an ovarian cancer model based on SauriCas9, and particularly discloses a recombinant plasmid for targeted knockout of Pten and Trp53 genes, and the recombinant plasmid comprises an EPI vector system. The recombinant plasmid takes an ori element as a replication start site, and sequentially comprises an sgRNA sequence of a targeted Trp53 gene and Pten controlled by double U6 promoters, a CAG promoter, a SauriCas9 nuclease expression unit, a fluorescent protein expression element, a resistance gene, an orip element and an EBNA1 protein expression element. The invention also discloses a method for rapidly establishing an ovarian cancer model based on SauriCas9, and the established ovarian cancer cell model. By adopting the method to construct the ovarian cancer cell model, the period from cell editing to animal tumor formation is shortened, the stability and immune integrity of the genetic background of the model are ensured, and large-scale drug screening and high-throughput experiments are facilitated.

Disclosed herein is an adenoviral vector system utilizing DARPin adapters. The system is highly effective, safe and able to deliver DNA in a cell-specific manner. It is demonstrated that the system is unexpectedly versatile, and can be used in conjunction with protein scaffolds, bioactive peptides and small molecules. This makes the system useful for numerous purposes, including the use of the system for therapeutic and diagnostic purposes.

The invention discloses a recombinant PB transposase mRNA (messenger ribonucleic acid) and PiggyBac vector system and application of the recombinant PB transposase mRNA and PiggyBac vector system. The invention provides a recombinant PB transposase mRNA (messenger ribonucleic acid), the nucleotide sequence of the recombinant PB transposase mRNA is shown as SEQ ID NO: 11, and the 5'end of the recombinant PB transposase mRNA contains a cap structure. The invention provides an mRNA type recombinant PB transposase: PBase-Cap-mRNA, so that the risk that a PB transposase plasmid is inserted into a host cell genome is avoided, and the efficiency of inserting a donor plasmid into the host cell genome is improved. The recombinant PB transposase mRNA is capped, so that the stability of the mRNA is improved, the translation of the mRNA is promoted, and the transposon efficiency is improved. The CHO cells are co-transfected by recombining PB transposase mRNA and donor plasmids, so that the efficiency of transfecting host cells by the donor plasmids is improved, and the construction period of stable cell strains is remarkably shortened.

Systems and methods for reducing latency through motion estimation and compensation techniques are disclosed. The systems and methods include a client device that uses transmitted lookup tables from a remote server to match user input to motion vectors, and tag and sum those motion vectors. When a remote server transmits encoded video frames to the client, the client decodes those video frames and applies the summed motion vectors to the decoded frames to estimate motion in those frames. The server instructs the client to receive input from a user, and use that input to match to cached motion vectors or invalidators. Based on that comparison, the client then applies the matched motion vectors or invalidators to effect motion compensation in a graphic interface. In this manner, latency in video data streams is reduced.

A dual vector system for treating ornithine transcarbamylase deficiency is provided. The system includes ((a) a gene editing AAV comprising a first AAV rh79 capsid and a first vector genome comprising a 5′ ITR, a sequence encoding a meganuclease that targets PCSK9 under control of regulatory sequences that direct expression of the meganuclease in a target cell comprising a PCSK9 gene, and a 3′ ITR; and(b) a donor AAV vector comprising a second AAV capsid and a second AAV rh79 vector genome comprising: a 5′ITR, a 5′ homology directed recombination (HDR) arm, a transgene encoding ornithine transcarbamylase (OTC) and regulatory sequences that direct expression of the transgene in the target cell, a 3′ HDR arm, and a 3′ ITR.

Recombinant myotropic AAV rh.74 capsids are described herein. In addition, plasmids, viral vectors, dual vector systems, cells, and compositions comprising or encoding such recombinant capsids are further described. Such recombinant polynucleotides, plasmids, viral vectors, dual vector systems, cells, and compositions may be used to treat muscle diseases or disorders, including muscular dystrophies and cardiomyopathies.

The invention discloses a vector system and method capable of converting mouse embryonic stem cells into embryonic-like cells in a 2-cell period, the vector system comprises a mouse Zfp352 gene sequence, and the nucleotide sequence of the mouse Zfp352 gene is shown as SEQ ID No.1. The invention also discloses a method for converting the mouse embryonic stem cells into embryonic-like cells in a 2-cell period. The invention creatively discovers that through overexpression of the Zfp352 in the mouse embryonic stem cells, the efficiency of converting the mouse pluripotent embryonic stem cells into the totipotent embryonic-like cells in the 2-cell period can be remarkably improved.

Disclosed herein a unique cell line system to generate a novel bovine adenovirus vector that provides more gene insertion capabilities and better immunogenicity for inserted antigens. The unique cell line is used for generating and growing of the new adenovirus vectors for gene delivery or recombinant vaccine production.

Systems and methods for reducing latency through motion estimation and compensation techniques are disclosed. The systems and methods include a client device that uses transmitted lookup tables from a remote server to match user input to motion vectors, and tag and sum those motion vectors. When a remote server transmits encoded video frames to the client, the client decodes those video frames and applies the summed motion vectors to the decoded frames to estimate motion in those frames. In certain embodiments, the systems and methods generate motion vectors at a server based on predetermined criteria and transmit the generated motion vectors and one or more invalidators to a client, which caches those motion vectors and invalidators. The server instructs the client to receive input from a user, and use that input to match to cached motion vectors or invalidators. Based on that comparison, the client then applies the matched motion vectors or invalidators to effect motion compensation in a graphic interface. In other embodiments, the systems and methods cache repetitive motion vectors at a server, which transmits a previously generated motion vector library to a client. The client stores the motion vector library, and monitors for user input data. The server instructs the client to calculate a motion estimate from the input data and instructs the client to update the stored motion vector library based on the input data, so that the client applies the stored motion vector library to initiate motion in a graphic interface prior to receiving actual motion vector data from the server. In this manner, latency in video data streams is reduced.

The present invention concerns a quasidystrophin (QD) having the structure CH1CH2H1R1R2R3H2R8R9 in its N-terminal part and advantageously further comprising the R16 and R17 rod domains, as well as the dual AAV vector system which allows producing it.

Novel nucleic acid compositions, vector systems, modified cells, isolated peptides, isolated nucleic acid sequences and pharmaceutical compositions that encode or express T cell receptor components directed against Jchain are provided herein. These novel components may be used to enhance an immune response in a subject diagnosed with a B cell associated disease or condition. Associated methods for treating such subjects are also provided herein.

Systems and methods for AI-assisted user training and flow query including receiving training including tokenizing the training data with a language learning model into one or more vectors, including a processing vector, and storing the one or more vectors. The systems and methods may receive a request from a user and generate a proficiency score by inputting the request into an adaptive response engine comprising the proficiency vector and proficiency logic and assign the proficiency score to the user. The systems and methods may generate a response associated with the request based on the proficiency score and programed query response logic and output the response.

The invention discloses a mini-NMD detection plasmid as well as a construction method and application thereof, a pNMD-3xFlag-Neo (EGFP) detection plasmid obtained by replacing an inserted gDNA fragment can realize detection of different gene mutations, and the mini-NMD detection plasmid is wide in application range and simple and convenient to operate; according to the method, a gDNA fragment needing to be inserted is smaller, vector construction is more efficient and rapid, and the problems that in-vitro NMD verification vector systems in the prior art are low in efficiency, poor in accuracy, tedious in detection process and the like are solved.

Systems and methods for performing entity resolution. In some aspects, the system obtains a plurality of attributes represented in a plurality of records from one or more sources. The system generates a plurality of match vectors based on the plurality of attributes. Each match vector includes a set of attributes that match between a pair of records and a remaining set of attributes that are not required to match between the pair of records. The system processes the plurality of match vectors using an entity resolution model trained to output a binary indicator regarding whether one or more pairs of records for a match vector be merged. The system merges the one or more pairs of records for each match vector of the plurality of match vectors having a corresponding binary indicator output from the entity resolution model that pairs of records for the match vector be merged.

A system can create a first graph that represents first values of current configurations of a computer hardware as first nodes and first dependencies of the current configurations as first links. The system can create first embedding vectors based on the first graph. The system can input the first embedding vectors to a graph isomorphism network to produce modified first embedding vectors. The system can identify specified configurations for the computer hardware. The system can create a second graph that represents second values of the specified configurations. The system can create second embedding vectors based on the second graph. The system can input the second embedding vectors to the graph isomorphism network to produce modified second embedding vectors. The system can perform a graph isomorphism evaluation on the modified first embedding vectors and the modified second embedding vectors to determine an amount of difference.

The present invention relates to the field of gene therapy in the medical field, and in particular to the use of overexpressing normal genes to restore hearing in patients with hereditary hearing loss caused by gene mutations or deletions. The present invention relates to a dual vector system expressing an OTOF protein. The dual vector system comprises two segments of nucleotide sequence, the first segment comprising two ITR sequences and a gene expression cassette inserted between the ITR sequences, and the second segment comprising two ITR sequences and a gene expression cassette inserted between the ITR sequences. An adeno-associated virus packaged with the vector is also provided. The vector and virus can restore hearing in both ears by administering them to one ear, in the field of large-scale dual vector gene delivery for hearing loss gene therapy.

The invention relates to a baculoviral vector system for improved delivery of DNA, RNA and protein into mammalian cells, including primary cells, tissues, and whole mammalian organisms.

The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and / or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.

The present disclosure provides polynucleotides, vector systems, cells, and methods for amplifying expression of proteins, such as AAV Rep and Cap proteins or therapeutic proteins (e.g., an antibody). Increased expression of AAV Rep and Cap proteins is useful in increasing production of recombinant AAV virions. Also provided herein are vector systems for inducing amplification of expression of AAV Rep and Cap proteins. Also provided herein are vector systems for inducing amplification of expression of therapeutic proteins. Inducible expression of therapeutic proteins is useful in increasing production of therapeutic proteins.

Recombinant myotropic AAV rh.74 capsids are described herein. In addition, plasmids, viral vectors, dual vector systems, cells, and compositions comprising or encoding such recombinant capsids are further described. Such recombinant polynucleotides, plasmids, viral vectors, dual vector systems, cells, and compositions may be used to treat muscle diseases or disorders, including muscular dystrophies and cardiomyopathies.

The present invention relates to a novel promoter derived from Corynebacterium and to a use of a variant thereof in the production of a protein or a rare sugar. In the present invention, a sod gene promoter derived from Corynebacterium ammoniagenes, which enables regulation of gene expression and exhibits significantly stronger activity compared to conventionally used promoters, was developed, promoter variants having various strengths were identified from the developed promoter, and by using the identified improved promoters, two enzymes capable of converting a common sugar into a rare sugar were highly expressed in a single vector system, thereby enabling production of a rare sugar via a one-pot reaction. Accordingly, the promoters can be utilized for the production of a target protein or a rare sugar.

The present invention generally relates to compositions, methods applications and screens used in functional genomics that focus on gene function in a cell and that may use vector systems and other aspects related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas systems and components thereof. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.